Hungarian drugmaker Gedeon Richter has signed an exclusive licensing agreement with US pharmaceutical giant Eli Lilly, a move that sent Richter's shares to a record high. Under the deal, Lilly gains worldwide rights to develop, manufacture, and sell combination therapies that pair Richter's estrogen, estetrol (E4), with Lilly's own medicines. The collaboration targets women's health and cardiometabolic conditions, two areas where both companies see significant growth potential.
What is estetrol (E4)?
Estetrol, often abbreviated as E4, is a naturally occurring estrogen produced by the fetal liver during pregnancy. It has been studied for its potential benefits in hormone replacement therapy (HRT) and contraception. Richter already sells E4 as a hormone replacement therapy under the brand name Fylrevy in the European Economic Area. The drug is also being evaluated for other uses, and Lilly has an option to help commercialize it in the US if regulators there approve it.
For Lilly, the deal fits into its broader strategy of expanding beyond its blockbuster diabetes and obesity drugs into other therapeutic areas. By combining E4 with its own compounds, Lilly hopes to create novel treatments that address unmet needs in women's health and cardiometabolic disease—conditions that often overlap, such as metabolic syndrome and cardiovascular risk in postmenopausal women.
The financial structure of the deal
Richter will receive an upfront payment at closing, though the exact amount was not disclosed. In addition, Richter is eligible for development and sales milestones, as well as tiered royalties based on net sales of any products that reach the market. This structure is common in pharmaceutical licensing deals, where the partner (Lilly) takes on most of the development and commercialization costs, while the licensor (Richter) benefits from future revenue streams without bearing the full risk.
Separately, Lilly has agreed to buy 381,354 Richter treasury shares for approximately $15 million, or about $39.33 per share. This share purchase is a notable element because it goes beyond a typical licensing contract. It aligns the two companies' interests and signals that Lilly is financially committed to the program's success. For investors, this can reduce the tendency to discount future milestone and royalty payments as uncertain "maybe later" income.
Why this matters for Richter's future
Richter's biggest challenge is the looming patent expiration on cariprazine, its top-selling antipsychotic. Cariprazine is sold in the US as Vraylar by AbbVie, and its patent protection is set to expire in 2030. When that happens, generic competition could significantly erode revenue. Analysts at Erste, a European bank, noted that a successful E4 program could become an important revenue source as Richter approaches that patent cliff.
By licensing E4 combinations to Lilly, Richter shifts much of the spending and rollout risk onto its partner. Instead of building a large global sales operation from scratch, Richter can rely on Lilly's established infrastructure. The upside for Richter comes through milestones and royalties, which can be higher-margin than running a big commercial organization. This approach is increasingly common among mid-sized pharma companies that lack the scale to compete globally on their own.
The deal also provides a bridge to 2030. While cariprazine remains a key revenue driver, the E4 partnership offers a potential new stream of income that could help offset the expected decline. The $15 million share purchase, while modest in absolute terms, is a signal of commitment that could reassure investors about the partnership's durability.
What it means for investors
For everyday investors, this deal illustrates how pharmaceutical companies manage patent cliffs—the period when a blockbuster drug loses exclusivity and faces generic competition. Companies often seek new products or partnerships well before the cliff arrives to smooth the transition. Richter's strategy is to leverage its expertise in E4 while letting a larger partner handle the heavy lifting of global development and sales.
The deal also highlights the growing interest in women's health and cardiometabolic conditions. These areas have historically been underfunded, but recent years have seen increased attention from both regulators and the industry. For investors, this could signal a broader trend of partnerships and acquisitions in these therapeutic spaces.
It's worth noting that the deal is not a guarantee of success. E4 combinations still need to go through clinical trials and regulatory approvals, which can take years and may fail. The milestones and royalties are contingent on those successes. However, the upfront payment and share purchase provide some immediate value to Richter, and the partnership reduces the risk of going it alone.
For those following the broader market, this deal is a reminder that partnerships and licensing agreements are a common way for smaller drugmakers to stay competitive. Similar dynamics can be seen in other sectors, such as Eramet seeking partners for its lithium and nickel projects or Codelco relying on private partners for copper output. In each case, companies are using partnerships to fund growth and manage risk.
As Richter moves toward 2030, investors will be watching how the E4 program progresses and whether it can deliver the revenue needed to offset the cariprazine patent loss. The deal with Lilly is a step in that direction, but the real test will come in the clinic and the marketplace.
